AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer

NEXT STORY
One Shot Keto Reviews – Legit Weight Loss Diet Pills or Fake Formula?
PREV STORY
Kronos Bio Comments on the Passing of Board Member John C. Martin, Ph.D.
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer

NEXT STORY
One Shot Keto Reviews – Legit Weight Loss Diet Pills or Fake Formula?
PREV STORY
Kronos Bio Comments on the Passing of Board Member John C. Martin, Ph.D.
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

MedAustron selected C-RAD Catalyst PT

MedAustron selected C-RAD Catalyst PT C-RAD announced today that it signed a purchasing agreement ...

author_avatar
NASDAQ Market News

Argos Therapeutics to Participate in Upcoming Investor Conferences

DURHAM, N.C., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an ...

author_avatar
NASDAQ Market News

Senator Percy Mockler sees connection between good vision and good outcomes

OTTAWA, ON, May 19, 2016 (GLOBE NEWSWIRE) -- May is Vision Health Month, and ...

author_avatar
NASDAQ Market News